Vasoactive Intestinal Peptide Promising Treatment for COVID-19 Respiratory Failure
Use of vasoactive intestinal peptide to treat critical COVID-19 respiratory failure in patients with comorbidities has shown promise.
Use of vasoactive intestinal peptide to treat critical COVID-19 respiratory failure in patients with comorbidities has shown promise.
Use of the COPD case-finding tool, CAPTURE, in US primary care practice demonstrated ability to provide critical in-study information to help guide protocol adjustment based on unforeseen events and to clearly outline COPD diagnostic processes.
Researchers studied the effect of income on quality of life in patients with cutaneous lupus erythematosus.
In patients with obstructive sleep apnea, BMI values increased significantly following CPAP therapy.
Machine learning modules can be trained with the use of electronic health record data to differentiate between transient and persistent cases of early childhood asthma
The use of noninvasive ventilation in patients with COPD while asleep may increase REM sleep time, decrease sleep onset latency, and the number of obstructive respiratory events.
Researchers assessed clinical features, muscle biopsy scores, and myositis-specific antibody profiles in juvenile dermatomyositis, and their association with disease outcomes and treatment responses in patients.
In this open-label extension study, researchers reported on the safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis.
In hospitalized patients with COVID-19, the routine use of molecular point-of-care testing in emergency department admissions was associated with a large reduction in time to results compared with laboratory PCR testing.
Systemic antibiotic treatment of acne may be associated with transient and persistent changes in the skin microbiota that may underlie skin comorbidities related to microbial dysbiosis.